Business Wire

MITTO-AG

4.4.2017 08:32:49 CEST | Business Wire | Press release

Share
Mitto AG Releases New White Paper Providing Strategies to Drive Business Through A2P Messaging

Mitto AG, a global SMS mobile messaging provider, has today released a new white paper, “Driving Business Through A2P Messaging.” The paper, authored by Juniper Research, a global leader for industry research and data, provides a comprehensive overview of how Mobile Network Operators, OTTs and Enterprises can use A2P messaging and its associated use cases to drive business and realize increased revenues.

Key findings include:

  • Consumer affinity with text messaging now extends to its A2P incarnation suggesting that the market has been seeded for additional use cases.
  • A2P messaging provides Mobile Network Operators with an opportunity to plug a growing cost-revenue deficit being caused by declining core revenues from voice, P2P messaging and data and increasing capex and opex costs.
  • While A2P messaging generated traffic worth nearly $36.3 billion in 2016, 31 percent of that traffic was grey route and not monetized, totaling nearly $11.9 billion in lost revenues to Mobile Network Operators.
  • OTT players are heavy users of A2P messaging, generating billions of traffic per annum in their use of A2P messaging for 2FA (two-factor authentication) and to re-engage users who have abandoned their messaging application or changed device.
  • The greatest financial benefit that A2P messaging can deliver to OTTs that provide content is in the form of an alternative billing mechanism with the value of digital content paid for via carrier billing projected to increase from $16.5 billion in 2016 to nearly $56.2 billion in 2021, an average annual growth of 28 percent.
  • Consumers prefer SMS as a means of communicating with companies over other channels including OTT messaging apps, Facebook/Skype and push notifications direct to a company’s app.

The white paper concludes with a series of recommendations from Juniper Research on the steps these three industries should take to increase revenues from A2P messaging. Those include the requirement to use carrier-grade messaging platforms or work with third party platform providers that can help stem grey route traffic and increase reach to deliver a robust and reliable global SMS connectivity offering.

“While companies know that the A2P opportunity is there, we find that more often than not, they don’t know how to take advantage of it for their own business benefits,” comments Andrea Giacomini, Managing Director, Mitto. “That’s why we engaged Juniper to write this white paper, to provide simple recommendations that companies can quickly implement to rapidly start realizing results from the mechanism.”

The white paper is available for complimentary download at http://go.mitto.ch/A2P_messaging_whitepaper .

About Mitto

With Headquarters in Zug, Switzerland and offices around the world, Mitto’s agile approach, trusted mobile operator relationships and carrier-grade SMS Messaging platform improve conversions and increase the speed and reliability of global mobile communications for the world’s largest OTTs, Enterprise and Mobile Operators. For more information visit mitto.ch , follow us on LinkedIn , Twitter or like us on Facebook .

Contact:

Mitto AG
Louise Finlay, +1 305-343-9122
louise@mitto.ch

Link:

ClickThru

Social Media:

https://www.facebook.com/Mitto.AG/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye